Nuvalent (NUVL) Other financing activities (2021 - 2026)
Nuvalent (NUVL) reported Other financing activities of $334000.0 for Q1 2026, up 5466.67% on a YoY basis from $6000.0 in Q1 2025, and down 11.17% quarter-over-quarter from $376000.0 in Q4 2025.
Nuvalent (NUVL) Other financing activities (2021 - 2026) Analysis & Trends
Nuvalent has reported Other financing activities for 5 years, with the latest figure at $334000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other financing activities rose 5466.67% year-over-year to $334000.0; the trailing twelve-month figure through Mar 2026 stood at $710000.0 (up 45.19% YoY), and the FY2025 full-year result was $382000.0, down 20.91% from the prior year.
- Other financing activities for Q1 2026 stood at $334000.0, down from $376000.0 in the prior quarter.
- The five-year high for Other financing activities was $766000.0 in Q4 2023, with the low at $6000.0 in Q1 2025.
- Historically, Other financing activities has averaged $293571.4 across 4 years, with a median of $295000.0 in 2024.
- Annual changes were most pronounced in 2024 — Other financing activities slumped 61.49% — and 2026, when it surged 5466.67%.
- Nuvalent's Other financing activities stood at $766000.0 in 2023, then tumbled by 61.49% to $295000.0 in 2024, then increased by 27.46% to $376000.0 in 2025, then slipped by 11.17% to $334000.0 in 2026.
- The last three Other financing activities figures came in at $334000.0 (Q1 2026), $376000.0 (Q4 2025), and $6000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 334,000.00 |
| Mar 31, 2026 | 334,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 295,000.00 |
| Dec 31, 2024 | 295,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Dec 31, 2023 | 766,000.00 |
| Dec 31, 2023 | 766,000.00 |
| Mar 31, 2023 | 90,000.00 |
| Mar 31, 2023 | 90,000.00 |
| Dec 31, 2021 | 371,000.00 |
| Dec 31, 2021 | 371,000.00 |
| Sep 30, 2021 | 2.23 Mn |
| Sep 30, 2021 | 2.23 Mn |